Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
This study is currently recruiting patients.
Sponsored by: |
Eastern Cooperative Oncology Group
|
Information provided by: |
National Cancer Institute (NCI) |
Purpose
RATIONALE: Drugs used in chemotherapy, such as doxorubicin work in different ways to stop tumor cells from dividing so they
stop growing or die. Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Combining
doxorubicin with bortezomib may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining doxorubicin with bortezomib in treating patients who have
liver cancer.
Condition
|
Treatment or Intervention |
Phase |
adult primary hepatocellular carcinoma advanced adult primary liver cancer recurrent adult primary liver cancer localized unresectable adult primary liver cancer
|
Drug: bortezomib Drug: doxorubicin Procedure: chemotherapy Procedure: enzyme inhibitor therapy
|
Phase II
|
MedlinePlus related topics: Liver Cancer
Study Type: Interventional
Study Design: Treatment
Official Title: Phase II Study of Doxorubicin and Bortezomib in Patients With Hepatocellular Carcinoma
Further Study Details:
OBJECTIVES: Primary
- Determine the tumor response rate in patients with hepatocellular carcinoma treated with doxorubicin and bortezomib.
Secondary
- Determine other parameters of antitumor effect, including time to tumor progression and overall survival, in patients treated
with this regimen.
- Determine the toxicity profile of this regimen in these patients.
- Compare proteasome 20S inhibition in tumor tissue (including proteins such as p21, p27, p53, Bax, and Bcl-2, that are affected
by proteasome 26S) with clinical parameters using biopsy specimens from patients treated with bortezomib.
- Determine phosphorylation of IkB in tumor tissue of patients treated with bortezomib.
- Compare phosphorylation of IkB in tumor tissue with clinical parameters using biopsy specimens obtained from patients treated
with bortezomib.
- Determine the effect of bortezomib on 26S proteasome activity in peripheral white blood cells and serum of these patients.
OUTLINE: This is a multicenter study.
Patients receive doxorubicin IV over 5-15 minutes on days 1 and 8. Patients also receive bortezomib IV over 3-5 minutes on
days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 10 courses in the absence of disease progression or unacceptable
toxicity. Patients with no disease progression may continue to receive bortezomib alone in the absence of disease progression
or unacceptable toxicity.
Patients are followed every 3 months for 2 years and then every 6 months for 1 year.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within 13 months.
Eligibility
Ages Eligible for Study:
18 Years and above,
Genders Eligible for Study:
Both
DISEASE CHARACTERISTICS:
- Microscopically confirmed hepatocellular carcinoma (HCC) not amenable to curative surgery
- Measurable disease amenable to biopsy
PATIENT CHARACTERISTICS: Age
Performance status
Life expectancy
Hematopoietic
- Absolute neutrophil count ≥ 1,500/mm^3 (without splenomegaly) OR ≥ 1,000/mm^3 (with splenomegaly)
- Platelet count ≥ 100,000/mm^3 (without splenomegaly) OR ≥ 75,000/mm^3 (with splenomegaly)
- No known bleeding diathesis
Hepatic
- AST ≤ 5 times upper limit of normal (ULN)
- Alkaline phosphatase ≤ 5 times ULN
- Bilirubin ≤ 2.0 mg/dL
- INR ≤ 1.5*
- PTT ≤ 1.5 times ULN*
- No Child-Pugh scale class C cirrhosis NOTE: *No vitamin K or fresh frozen plasma to correct laboratory values just prior to
biopsy or study enrollment
Renal
Cardiovascular
- Ejection fraction ≥ 50% by echocardiogram or MUGA
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No known allergy to boron, mannitol, or bortezomib
- No peripheral neuropathy > grade 1
- No history of other untreated malignancy
- No underlying medical condition that would preclude study participation
- No psychiatric illness or continued alcohol abuse that would preclude study compliance and giving informed consent
- No other malignancy within the past 5 years except carcinoma in situ of the cervix or previously treated squamous cell or
basal cell skin cancer
PRIOR CONCURRENT THERAPY: Biologic therapy
- No concurrent prophylactic hematopoietic growth factors
Chemotherapy
- No prior systemic chemotherapy for HCC
- No prior chemoembolization
- At least 4 weeks since prior antineoplastics for non-malignant disease (e.g., methotrexate for rheumatoid arthritis) and recovered
Endocrine therapy
- No prior tamoxifen for HCC
Radiotherapy
Surgery
Other
- Prior embolization (without chemotherapy), ethanol injection, radiofrequency ablation, or cryosurgery allowed provided there
is documented disease progression within the involved lesion or at least 1 previously untreated lesion amenable to biopsy
- No prior octreotide for HCC
- No concurrent verapamil
Location
and Contact
Information
Georgia Winship Cancer Institute of Emory University, Atlanta,
Georgia,
30322,
United States; Recruiting
William Costin Wood, MD
404-778-5180
Illinois Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago,
Illinois,
60611,
United States; Recruiting
Al Bowen Benson, MD, FACP
312-695-1382
New York NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York,
New York,
10016,
United States; Recruiting
Pennsylvania Abramson Cancer Center at University of Pennsylvania Medical Center, Philadelphia,
Pennsylvania,
19104,
United States; Recruiting
Daniel G. Haller, MD
215-662-6318
Fox Chase Cancer Center, Philadelphia,
Pennsylvania,
19111-2497,
United States; Recruiting
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia,
Pennsylvania,
19107-5541,
United States; Recruiting
William J. Tester, MD
215-456-3800
Tennessee Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center, Nashville,
Tennessee,
37232-6307,
United States; Recruiting
Study chairs or principal investigators
Jordan D. Berlin, MD, Study Chair, Vanderbilt-Ingram Cancer Center
Bruce J. Giantonio, MD, University of Pennsylvania Health Systems
William Chapman, MD, Barnes-Jewish Hospital
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Study ID Numbers:
CDR0000363801; ECOG-E6202
Record last reviewed:
August 2004
Record first received:
May 14, 2004
ClinicalTrials.gov Identifier:
NCT00083226Health Authority: Unspecified
ClinicalTrials.gov processed this record on 2004-11-18